CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
免疫治疗与癌症疫苗研发
英文原题：Immunotherapy and cancer vaccine development.
查看英文原题
Immunotherapy and cancer vaccine development.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
在T细胞上发现免疫检查点蛋白PD-1和CTLA-4，并获FDA批准使用针对这些分子的抗体增强抗癌免疫，开启了癌症免疫治疗时代，也推动研究者寻找并确立免疫系统中其他可作为治疗靶点的关键因子。增强抗癌免疫应答的策略主要有三类：1）免疫检查点阻断疗法使用拮抗性或激动性抗体，分别靶向免疫系统关键细胞或细胞类型上的抑制性和刺激性蛋白；2）癌症疫苗疗法以癌细胞表达的异常蛋白或抗原为靶点开发疫苗；3）CAR-T 细胞疗法通过生成表达特异性受体的重组T细胞，使其以抗原依赖方式识别并清除癌细胞。
展开英文摘要原文
Identification of immune checkpoint proteins, PD-1 and CTLA-4 on T cells and the FDA approval of antibodies targeting them to boost anti-cancer immunity has ushered in the era of cancer immunotherapy and motivated the identification and establishment of additional key players of the immune system as viable therapeutic targets.
Three distinct approaches have been developed as means to enhance the immune response against cancer: 1) Immune checkpoint blockade therapy utilizes antagonistic or agonistic antibodies against inhibitory and stimulatory proteins respectively on key cells or cell types of the immune system, 2) Cancer vaccine therapy uses abnormal proteins/antigens expressed on cancer cells as targets for cancer vaccine development and 3) CAR-T cell therapy involves the generation of recombinant T cells that express specific receptors enabling the recognition and elimination of cancer cells in an antigen-dependent manner.
论文信息
- 作者
- Nagarajan A、Jayaprakash P
- 单位
- MD Anderson Cancer Center, Houston, Texas, United States. Electronic address: anagarajan@mdanderson.org.United States
- 期刊
- Methods in cell biology2025
- 原文标识
- PubMed 41033722 · DOI 10.1016/bs.mcb.2025.06.001